MARUHO AND SKYEPHARMA SIGN DEVELOPMENT AND MARKETING AGREEMENT FOR DEPOBUPIVACAINE IN JAPAN
Maruho Company Limited ("Maruho") and SkyePharma PLC announce that
they have entered into a strategic agreement for the development, marketing
and distribution of DepoBupivacaine(TM) in Japan. DepoBupivacaine(TM) is SkyePharma's
novel sustained-release injectable formulation of the local anaesthetic bupivacaine
and is designed to provide localised pain relief for more than 48 hours after
a surgical operation.